Clinical Trial Update: Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery [Phase 2]

View source ↗

Summary

Phase 2 study evaluating a single intravenous dose of TB-402 for prophylaxis of venous thromboembolism after total hip replacement has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• TB-402

Snippet

Sponsor: ThromboGenics | Conditions: Prophylaxis of Venous Thromboembolic Events | Phase 2 | Status: COMPLETED